{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-24-000042","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.965089+00:00","generated_at":"2026-05-31T02:21:31.860479+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen enrolls first subject in PALISADE-4 Phase 3 trial of fasedienol for SAD","bullets":["First subject enrolled in PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder (SAD).","Fasedienol is an investigational neuroactive pherine candidate in U.S. registration-directed Phase 3 development.","Over 30 million Americans suffer from SAD; no FDA-approved acute treatments currently available.","Fasedienol targets nose-to-brain neural circuits to reduce fear and anxiety associated with SAD.","CEO Shawn Singh confirmed the milestone was achieved as planned in the registration-directed program."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-24-000042","json":"https://secwatch.observer/filing/0001411685-24-000042.json","markdown":"https://secwatch.observer/filing/0001411685-24-000042.md","text":"https://secwatch.observer/filing/0001411685-24-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168524000042/0001411685-24-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168524000042/vtgn-20240923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:21:31.860479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}